CN102579458A - Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis - Google Patents
Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis Download PDFInfo
- Publication number
- CN102579458A CN102579458A CN2012100593667A CN201210059366A CN102579458A CN 102579458 A CN102579458 A CN 102579458A CN 2012100593667 A CN2012100593667 A CN 2012100593667A CN 201210059366 A CN201210059366 A CN 201210059366A CN 102579458 A CN102579458 A CN 102579458A
- Authority
- CN
- China
- Prior art keywords
- infusion
- medicament
- drug
- pain
- phlebitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicament formula for relieving pain caused by infusion medicament and preventing phlebitis. The medicament formula can be used for relieving pain caused by intravenous supplementing potassium, infusion mannitol, azithromycin, fructose diphosphate sodium and chemotherapeutic medicaments, and can be used for effectively preventing and treating extravasation phlebitis caused by long-term use of a remaining needle, infusion of vein high-nutrition medicaments, infusion of chemotherapeutic medicaments, infusion extravasation and the like. According to the medicament formula, 20-35ng of anisodamine, 6-13ml of lidocaine, 15-26mg of dexamethasone and 4-6ml of glycerin are arranged in a sterile kidney basin, sterile gauze is coated above a puncture part after being uniformly wetted, and an external preservative film is wound on the gauze. The medicinal formula has the advantages of continually and efficiently relieving local pain caused by infusion medicaments, and effectively preventing and treating local inflammation, swelling pain and stripped cable change caused by infusion.
Description
Affiliated technology neck
The present invention relates to alleviation dead point medicine pain and the phlebitic pharmaceutical formulation of control by three kinds of medicines and a kind of solvent composition.
Background technology
Use at present hot compress can alleviate dead point drug-induced pain, because of vasodilation, blood flow is accelerated, and blood drug level can reduce and helps the pain respite, but lacks persistency, can't ensure medicine continue carry out smoothly.In use be also noted that according to individual variation and regulate water temperature, especially old people and children's, prevent and treat scald.Use 50% magnesium sulfate external application for curing phlebitis; Though can play the effect of removing pain, swelling; But because Adlerika character is unstable, receive the external environment influence easily, exist solution to be prone to separate out crystallization and make that gauze is dry, the characteristics of hardening; The patient feels under the weather, and curative effect owes desirable.
Summary of the invention
Be to restrain hot compress and alleviate dead point drug-induced pain, lack the deficiency of dauer effect, the sustainable part that efficiently acts on of drug formulation provided by the present invention, effective alleviating pain, ensure medication continue carry out smoothly.Separate out the crystallization hardening for what overcome that 50% magnesium sulfate external application for curing phlebitis caused, curative effect is owed ideal characteristics, and pharmaceutical formulation provided by the present invention is is effectively prevented and treated the change of local red and swollen, distending pain and bar rope appearance due to the transfusion reason.
The present invention will solve the technical scheme that its technical problem adopts: get Anisodamine 20-35mg, lignocaine 6-13ml dexamethasone 15-26mg.Glycerol 4-6ml puts in the aseptic kidney basin, evenly drenches to spread on puncture place top behind the sterile gauze, and the external preservative film is wrapped on the gauze.This drug formulation can effectively be alleviated vein kalium replenishment, dead point mannitol, azithromycin, Fructose Diphosphate sodium, chemotherapy class drug-induced pain; Also can prevent and treat because of induced phlebitis that exosmoses such as life-time service remaining needle, defeated intravenous hyperalimentation medicine, defeated chemotherapeutics, transfusion extravasations, local redness, distending pain and bar rope appearance are changed has good effect.
The invention has the beneficial effects as follows: this drug formulation can effectively be alleviated dead point drug-induced pain and prevent and treat phlebitis, and is simple to operate, and persistent is ensureing irritating medicine smoothly in the input, and the control of the induced phlebitis that exosmoses is had good effect.
Description of drawings
Below in conjunction with molecular formula and embodiment the present invention is further specified
Fig. 1 is alleviated dead point drug-induced pain and the phlebitic drug formulation sketch map of control, and among the figure: last figure is the dexamethasone sodium phosphate molecular formula, and middle figure is the lignocaine molecular formula, and figure below is the raceanisodamine molecular formula.
Specific embodiment
1, Yang Tianhe (admission number 176660) man, 27 years old, rupture of spleen, fracture of rib, defeated Fructose Diphosphate sodium and potassium chloride use drug formulation alleviating pain of the present invention, and respond well to failing the induced phlebitis that exosmoses that the zest medicinal liquid causes for a long time.
2, Li Xinhong (admission number 179862) woman, 40 years old, left breast cancer, the swelling of the local pain that defeated chemotherapeutic causes and skin blackout, uses drug formulation of the present invention after, pain is obviously alleviated, it is obvious that the swelling of turning black alleviates effect.
3, Zhang Wenshan (admission number 175941) man, 72 years old, patient behind the laparoscopic cholecystectomy, defeated intravenous hyperalimentation liquid and potassium chloride, uses drug formulation of the present invention after, pain is obviously alleviated, and transfusion place skin turgor effect is satisfied with.
Claims (4)
1. alleviate dead point drug-induced pain and the phlebitic drug formulation of control
This drug formulation is got Anisodamine 20-35mg, lignocaine 6-13ml, dexamethasone 15-26mg, glycerol 4-6ml, puts in the aseptic kidney basin, evenly drenches to spread on puncture place top behind the sterile gauze, and the external preservative film is wrapped on the gauze.
2. its technical characterictic is: guarantee that medicine is aseptic and efficiently permeate through skin, can play effective alleviation dead point drug-induced pain and the phlebitic effect of control.
3. drug formulation according to claim 1 is characterized in that: can alleviate the vein kalium replenishment, dead point mannitol, azithromycin, Fructose Diphosphate sodium, the local congestion and swelling pain of chemotherapy class drug-induced.
4. drug formulation according to claim 1 is characterized in that: also can effectively prevent and treat because of induced phlebitis that exosmoses such as life-time service remaining needle, defeated intravenous hyperalimentation medicine, defeated chemotherapy class medicine, transfusion extravasations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100593667A CN102579458A (en) | 2012-03-08 | 2012-03-08 | Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100593667A CN102579458A (en) | 2012-03-08 | 2012-03-08 | Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579458A true CN102579458A (en) | 2012-07-18 |
Family
ID=46469065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100593667A Pending CN102579458A (en) | 2012-03-08 | 2012-03-08 | Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579458A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104382930A (en) * | 2014-10-27 | 2015-03-04 | 袁继美 | Liquid medicine for treating mannitol infusion leakage |
| WO2017040767A1 (en) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Therapeutic compounds for pain and synthesis thereof |
| CN109939115A (en) * | 2019-05-06 | 2019-06-28 | 河南中医药大学 | A kind of compound suppository of therapeutic radiation rectitis |
-
2012
- 2012-03-08 CN CN2012100593667A patent/CN102579458A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 任泽凤等: "地塞米松、利多卡因、654-2对化疗药物血管外渗防护作用的研究", 《中国实用护理杂志》 * |
| 王秀云等: "甘油、利多卡因、山莨菪碱混合液局部涂布对静脉穿刺效果的研究", 《现代护理》 * |
| 王翠等: "利多卡因加山莨菪碱湿敷预防甘露醇引起的静脉炎", 《中国护理研究》 * |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104382930A (en) * | 2014-10-27 | 2015-03-04 | 袁继美 | Liquid medicine for treating mannitol infusion leakage |
| CN109071540B (en) * | 2015-09-04 | 2021-06-04 | 詹森药业有限公司 | Therapeutic compounds for pain and synthesis thereof |
| TWI686393B (en) * | 2015-09-04 | 2020-03-01 | 比利時商健生藥品公司 | Therapeutic compound for pain and synthesis thereof |
| WO2017040772A1 (en) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Therapeutic compounds and synthesis |
| CN108290890A (en) * | 2015-09-04 | 2018-07-17 | 詹森药业有限公司 | Therapeutic compound and synthesis |
| CN108495854A (en) * | 2015-09-04 | 2018-09-04 | 詹森药业有限公司 | Therapeutic compound for pain and its synthesis |
| TWI641608B (en) * | 2015-09-04 | 2018-11-21 | 比利時商健生藥品公司 | Therapeutic compounds for pain and synthesis thereof |
| WO2017040770A1 (en) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Therapeutic compounds for pain and synthesis thereof |
| CN108495854B (en) * | 2015-09-04 | 2021-10-15 | 詹森药业有限公司 | Therapeutic compounds for pain and synthesis thereof |
| CN109071540A (en) * | 2015-09-04 | 2018-12-21 | 詹森药业有限公司 | Therapeutic compound and its synthesis for pain |
| US10766898B2 (en) | 2015-09-04 | 2020-09-08 | Janssen Pharmaceutica Nv | Therapeutic compound for pain and synthesis thereof |
| TWI713879B (en) * | 2015-09-04 | 2020-12-21 | 比利時商健生藥品公司 | Therapeutic compounds for pain and synthesis thereof |
| WO2017040767A1 (en) * | 2015-09-04 | 2017-03-09 | Janssen Pharmaceutica Nv | Therapeutic compounds for pain and synthesis thereof |
| CN108290890B (en) * | 2015-09-04 | 2021-08-06 | 詹森药业有限公司 | Therapeutic compounds and synthesis |
| CN109939115A (en) * | 2019-05-06 | 2019-06-28 | 河南中医药大学 | A kind of compound suppository of therapeutic radiation rectitis |
| CN109939115B (en) * | 2019-05-06 | 2021-11-02 | 河南中医药大学 | Compound suppository for treating radiation proctitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015109296A (en) | MEDICINAL DELIVERY SYSTEMS AND METHODS FOR TREATMENT OF BLADDER CANCER, INCLUDING THE USE OF OXALIPLATIN | |
| CN102579458A (en) | Medicament formula for relieving pain caused by infusion medicament and preventing phlebitis | |
| CN105147726A (en) | Medical application preventing and curing phlebitis and preparing method thereof | |
| CN204092838U (en) | A kind of package therapeutic instrument comprising ultra micro Chinese medicinal powder | |
| CN103784524A (en) | Preparation method and application of traditional Chinese medicine compound transdermal preparation capable of inhibiting inflammation and suppressing pains | |
| CN103990118B (en) | A kind for the treatment of injects the combination medicament that somatomedin causes hypertrophy | |
| CN108186944A (en) | A kind of hemorrhoid inject cream | |
| CN103385907A (en) | Rhinitis slow-release drug | |
| CN103989712A (en) | Traditional Chinese medicine for treating facial paralysis and preparation method thereof | |
| CN109223890A (en) | A kind of composition for premature ejaculation sex dysfunction | |
| CN107982371A (en) | A kind of Chinese medicine preparation for treating nerve deafness | |
| CN202620365U (en) | Medicament concentration adjustable patient controlled analgesia | |
| CN105413042A (en) | Y-shaped tube capable of preventing side tube of double-cavity peripheral catheter from being blocked | |
| CN105250330A (en) | Compound salicylic acid beriberi powder for treating beriberi and preparation method thereof | |
| CN101596228A (en) | The new purposes of pain-relieving plaster for injury and rheumatism | |
| CN103405495A (en) | Traditional Chinese medicine injection for treating rhinitis | |
| CN106138735A (en) | A kind of eliminating stagnation eliminating carbuncle treatment cream | |
| CN106728350A (en) | A kind of medicine for treating paralysis | |
| CN107982339A (en) | A kind of Chinese medicine preparation for treating tympanitis | |
| CN103263524A (en) | Traditional Chinese medicine cream for promoting tuberculosis wound healing | |
| CN105641105A (en) | Medicine for treating swollen sore throat | |
| CN105641116A (en) | Drug for treatment of ovarian cyst | |
| CN107982368A (en) | A kind of Chinese medicine preparation for treating acute suppurative otitis media | |
| CN105456613A (en) | Traditional Chinese medicine formula of medicinal liquor for treating chloasma | |
| CN109125497A (en) | A kind of Chinese medicine for treating chronic cephalalgia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120718 |